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12y.o.), 55.4% were women. The average cost person/year was
euro 3502.87; 73.9% attributable to hospitalisations, 17.5% to
drugs, 8,6% to other medical costs. The 32.8% patients died
during the follow up period, with a mean age of 84 ± 9 statisti-
cally different (p < 0.0001) from survivors (mean age 74 ± 11
y.o.). CONCLUSIONS: Stroke imposes a large social and eco-
nomic burden on NHS and society because of the large number
of hospitalisation and the high rate of mortality. Future investi-
gations will be conduct to asses the relationships between comor-
bidity, costs, drug therapy and survival.
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FIRST-EVER ISCHEMIC STROKE
Tseng MC1, Chang KC2
1National Sun Yat-Sen University, Kaohsiung,Taiwan; 2Chang Gung
Memorial Hospital, Kaohsiung County,Taiwan
OBJECTIVES: To assess factors inﬂuencing acute hospitalization
for patients with ﬁrst-ever ischemic stroke in Taiwan.
METHODS: Data were prospectively collected from 360 ﬁrst-
ever ischemic stroke patients consecutively admitted to a medical
center within 48 hours after symptom onset. Longer stay was
deﬁned as length of stay (LOS) >7 days after admission in depart-
ment of neurology for acute care. The association between demo-
graphic characteristics or clinical variables and LOS was
examined using multivariate logistic regression analysis. Dis-
crimination of the model was assessed by the area under the
receiver operating characteristic curve, and calibration was
assessed using goodness of ﬁt test. RESULTS: Patients (58%
male) had mean age 64.9 ± 12.7 (range, 18 to 93) years. Median
National Institutes of Health Stroke Scale (NIHSS) score at
admission was 6 (25th to 75th percentile, 3 to 12), median mod-
iﬁed Barthel Index (MBI; on a scale of 0 to 20) at admission was
12 (25th to 75th percentile, 5 to 16). The LOS was >7 days in
169 (47%) patients. Male sex (odds ratio [OR], 1.7; 95% CI,
1.0 to 2.8), baseline NIHSS score 7–15 (versus 0–6) (OR, 2.9;
95% CI, 1.5 to 5.7), baseline NIHSS score ≥16 (versus 0–6) (OR,
3.1; 95% CI, 1.3 to 7.4), baseline MBI ≥12 (OR, 0.5; 95% CI,
0.3 to 1.0), and small vessel occlusive subtype (OR, 0.35; 95%
CI, 0.2 to 0.6) were independent predictors of longer stay. Good-
ness-of-ﬁt test (Hosmer-Lemeshow test) was not signiﬁcant (P =
0.49), indicating adequate ﬁtness. The model’s discrimination
was adequate with an under the curve area (receiver operating
characteristic curve) of 0.776. CONCLUSIONS: The impact of
stroke severity need to be understood to manager LOS. Early
supported discharge planning would probably reduce the LOS
in acute hospitalization of this group of ﬁrst-ever ischemic stroke
patients.
PST7
DO PATIENTS WITH ATRIAL FIBRILLATION RECEIVE
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OBJECTIVES: Clinical practice guidelines and several clinical
trials support the use of warfarin for stroke prevention in most
patients with atrial ﬁbrillation (AF). Warfarin should not be used
in cases where contraindications exist or the risk of stroke is low.
It is not clear what proportion of are there patients at risk of
stroke and without contraindications do not receive warfarin in
practice. METHODS: A MEDLINE search was conducted
(1966–2001) using the MeSH terms anticoagulants, AF, warfarin
and cerebrovascular disorder (prevention and control). Practice-
based studies reporting the proportion of patients eligible to
receive warfarin (i.e., no contraindications to thromboprophy-
laxis and at moderate or high risk of stroke) who actually
received warfarin for stroke prevention in AF were retrieved.
RESULTS: Twenty-one practice-based studies were found, of
which 3 were excluded because the patient population or
centre/setting signiﬁcantly varied from the other identiﬁed
studies. Approximately 47–89% of patients enrolled in the
remaining 18 studies were eligible for stroke prevention. Only
15–64% of eligible patients received warfarin and 15–56% did
not receive any form of stroke prevention therapy at all (i.e., no
warfarin or antiplatelet agent). CONCLUSIONS: Despite the
publication of multiple clinical trials and practice guidelines sup-
porting the use of warfarin for stroke prevention in AF, many
eligible patients do not receive appropriate preventive therapy,
and therefore remain at increased risk of stroke. Reasons for the
sub-optimal use of warfarin for stroke prevention in AF require
further research.
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OBJECTIVES: There is a documented lack of treatment and
undertreatment with warfarin in AF patients. GPs and Special-
ists (SPs) may take different approaches to anticoagulation for
their AF patients. The objective is to identify, compare and 
quantify warfarin patient segments for both SPs and GPs.
METHODS: Physicians from Toronto, Montreal and Vancouver,
randomly recruited from lists of high warfarin prescribers, par-
ticipated in 60 minute qualitative interviews. Thirty-Six physi-
cians were interviewed (14GPs, 8 Cardiologists, 6 Internists and
3 Haematologists). RESULTS: SPs placed patients in 3 major 
segments: untreated (5% of their patients), treated (90–95%)
and undertreated (5%). GPs had only 2 segments: untreated
(10–25%) and treated (75–90%). Both physician groups identi-
ﬁed untreated patients as those at risk of falling, demented, prone
to bleed, immobile or refusing treatment. SPs referred to under-
treated patients as those using ASA. GPs saw ASA users as part
of their treated group. The other segment within the GP treated
group was warfarin users. SPs divided their treated segment into
well-controlled and not well-controlled. CONCLUSION: SPs
and GPs use similar criteria in determining which patients do not
receive warfarin. However, views on the value of ASA seem dif-
ferent. Further, GPs in this study did not distinguish between well
and not-well controlled warfarin, but rather indicated ASA vs.
warfarin users are both considered treated. Further research is
required to further investigate the differences in opinion, lack of
treatment and to quantify each segment.
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OBJECTIVES: To assess the properties of the Mandarin version
of the Stoke Impact Scale (SIS) versions 3.0, developed by Pamela
W. Duncan et al. METHODS: The SIS, a stroke-speciﬁc outcome
measure, assesses 8 domains: strength (4 items), memory (7
items), emotion (9 items), communication (7 items), activities of
daily living/instrumental activities of daily living (ADL/IADL)
(10 items), mobility (9 items), hand function (5 items), and par-
ticipation (8 items). SIS was translated and back-translated
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according to the standardized guidelines for cross-cultural adap-
tation. Patients consecutively admitted with ischemic stroke were
recruited, until 30 patients in each of three groups of stroke
severity were reached. Stroke severity was evaluated with NIH
stroke scale and categorized as mild (0–6), moderate (7–15), or
severe (16–38). Patients were assessed 3 times, within 7 days of
admission, 3 months and 6 months afterwards. Ten randomly
selected patients were re-administered 2 weeks after ﬁrst admin-
istration for test-retest study. RESULTS: We studied 50 mild, 36
moderate, and 33 severe stroke patients. Cronbach’s alpha was
high for 6 domains (0.95 to 0.98), moderate for emotion (0.69)
and participation (0.77). Intraclass correlation coefﬁcients
ranged from 0.63 to 0.89, except for memory (0.13), hand func-
tion (0.47), and ADL/IADL (0.53). Based on ﬁrst assessment,
memory and communication may have potential for ceiling
effects in mild stroke group, strength and hand function may
have potential for ﬂoor effects in moderate stroke group, and all
domains may have potential for ﬂoor/ceiling effects in severe
stroke group. The correlations between each of the physical
domains (strength, ADL/IADL, mobility, hand function) and
Barthel Index were good (0.72 to 0.92). Memory domain
showed a high correlation with MMSE (0.81). CONCLUSIONS:
The Mandarin version of the SIS is an acceptable stroke-speciﬁc
outcome measure in most domains. Further studies in determin-
ing the content should enhance conﬁdence in its validity.
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OBJECTIVES: To present steps involved in launching the ﬁrst
national, prospective study determining resource utilization and
direct (hospitalization, rehabilitation, outpatient, community
care) and indirect (lost productivity, caregiver) costs of manag-
ing ischemic stroke in the ﬁrst 6-months post-stroke.
METHODS: A prospective, observational study was designed.
A cohort (N = 200) of ischemic stroke patients will be recruited
in a consecutive manner by stroke centres across Canada. Ethics
approvals will be obtained and a minimum of one neurologist
and one study coordinator per centre will participate to identify
eligible patients, obtain informed consent, and interview
patients. Three sets of questionnaires (baseline, 3-months, and
6-months) will be completed. Questionnaires include clinical and
drug histories, stroke severity, disability, resource utilization,
depression and utility. Patients will also complete diaries to quan-
tify indirect costs. A pilot study will be conducted to evaluate
the study tools. Data collected will be entered electronically via
a secure website. RESULTS: Ten stroke centres across Canada
(Ottawa, Toronto, Calgary, Montreal, Quebec City, Edmonton,
Vancouver, Halifax, Saint John and Thunder Bay) will each
recruit 20 eligible ischemic stroke patients into this study. Inclu-
sion criteria such as age, language, neuroimaging evidence and
non-interventional clinical trial involvement have been deﬁned
in order for the study to be launched on September 26, 2005
(with a 3-month recruitment period) and end July 2006. The
primary analysis will provide an overall estimate of costs per
ischemic stroke patient. Sub-analyses for atrial ﬁbrillation and
severity will also be conducted. CONCLUSIONS: The BURST
study will be the ﬁrst Canadian study that will determine the
resource utilization and overall costs of treating ischemic stroke
in both acute and post-acute settings with participation from ter-
tiary-based and community-based stroke centres. The economic
data collected will be critical for future stroke care funding
systems.
PST11
THE USE OF MULTI-CRITERIA DECISION METHODS IN
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OBJECTIVES: To investigate how the choice of multicriteria
decision method inﬂuences outcome (ranking criteria and crite-
ria weights). Population. A convenience sample of 28 subjects,
12 healthy and 16 cognitively impaired. METHODS: Based on
a literature review, 5 multicriteria methods were chosen for com-
parison including: Kepner-tregoe analysis (KTA), simple multi
attribute rating technique (SMART), SMART using swing
weights (SWING), Analytic Hierarchy Process (AHP) and Con-
joint Analysis (CA). Four attributes of treatment were identiﬁed
(impact, duration, and end-result of treatment and associated
risks). Subjects were asked to both rank and rate the importance
of these attributes with each method. The order of methods was
randomized and the total length of the interview was restricted
to one hour. Some subjects therefore did not use all methods.
Subjects were interviewed either once (n = 14) or twice (n = 14)
(Only the results of the ﬁrst measurement are presented)
RESULTS: The highest percentages of rank reversals were found
between CA and other methods (55–62%). The lowest percent-
age of rank reversals was between KTA and SMART (18%). The
percentage of rank reversals was signiﬁcantly higher in impaired
population (An average of 54% compared to 36% in unimpaired
population). When comparing actual weights, AHP and SMART
correlate highly with all other methods except CA. CONCLU-
SIONS: The high percentages in rank reversal and divergent 
correlation between individual weights (especially CA compared
to other methods) show that the method chosen inﬂuences
outcome. This has to be taken into account when the ranks or
weights are used in multi-criteria decision analysis to make
actual treatment decisions. The dissimilar methodology of CA
might explain the high percentages of rank-reversals and low
correlation between this method and other. Also, the design of
the survey might have inﬂuenced CA weights and ranking.
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OBJECTIVES: To select the best multi-criteria decision making
method for use with cognitively impaired patients. Population.
A convenience sample of 28 subjects, 12 healthy and 16 cogni-
tively impaired. METHODS: Based on a literature review, 5 mul-
